68results about "Nuclear receptor" patented technology

Disclosed herein is a genetically engineered mesenchymal stem cells (MSC) comprising genetic alterations that increase gene expressions for adipogenic differentiation, mitochondrial biogenesis and a brown adipocyte marker. Also disclosed herein is a pharmaceutical composition and use of the pharmaceutical composition for preventing, ameliorating and / or treating a metabolic disorder.

Described herein are compositions for modulating a molecule in a cell. Also described herein are methods for modulating a molecule in a cell.

Provided are chimeric AP-1 transcription factor polypeptides. In some aspects, provided are chimeric polypeptides comprising an N-terminal domain of a first AP-1 transcription factor and a bZIP domain of a second AP-1 transcription factor. Such polypeptides may further comprise a C-terminal domain of an AP-1 transcription factor. In other aspects, provided are chimeric polypeptides comprising a bZIP domain of a first AP-1 transcription factor and a C-terminal domain of a second AP-1 transcription factor. Such polypeptides may further comprise an N-terminal domain of an AP-1 transcription factor. In some instances, T cells expressing the chimeric AP-1 transcription factor polypeptides exhibit enhanced T cell function relative to T cells expressing only native wild-type AP-1 transcription factors. Also provided are T cells expressing the chimeric polypeptides and methods of using such cells to treat a condition (e.g., cancer, infection, and / or the like) in a subject in need thereof.

The aim of the present invention is to provide a new method for tumor treatment by mediating overexpression of HNF4α in tumor cells using self-replicating RNA and inducing the differentiation of tumor cells into mature cells, thereby suppressing the growth of tumor cells. [Solution] A gene delivery system consisting of a nucleic acid vector and a delivery vehicle, wherein the nucleic acid vector is a self-replicating RNA carrying HNF4α, the gene delivery system delivers HNF4α into tumor cells and induces the differentiation of tumor cells into normal mature cells, the self-replicating RNA is based on an engineered alphavirus genome and has a 35-100 nt polyadenylic acid tail, and the delivery vehicle is a lipid nanoparticle.

The present disclosure provides AAV vectors encoding modified chimeric ligand gated ion channels and methods for treating trigeminal neuralgia in a subject in need thereof.

The present invention relates to compositions and methods for treating cancer with chimeric antigen receptors.

To suppress growth of tumor cells and provide novel means for tumor treatment by inducing differentiation of tumor cells into mature cells by mediating overexpression of HNF4α in tumor cells by self-replicating RNA.SOLUTION: Provided is a gene delivery system comprising a nucleic acid vector and a delivery vehicle. Therein the nucleic acid vector is a self-replicating RNA carrying HNF4α; the gene delivery system delivers HNF4α into tumor cells and induces differentiation of the tumor cells into normal mature cells; the self-replicating RNA is based on one engineered alphavirus genome and has a polyadenylic acid tail of 35-100 nt; and the delivery vehicle is a lipid nanoparticle.SELECTED DRAWING: Figure 23

To provide a composition comprising an epitope of a peptide that may elicit an immune response in a subject following administration.SOLUTION: Such a composition may comprise a nucleic acid. The composition may comprise a peptide. The method disclosed herein comprises a step of administering a composition comprising an epitope of a peptide to a subject in need thereof. In some of aspects, the composition disclosed herein comprises [a first plasmid comprising] a first nucleotide sequence encoding a first epitope of a first antigen expressed by a cell associated with breast cancer, and a second plasmid comprising a second nucleotide sequence encoding a second epitope of a second antigen expressed by a cell associated with breast cancer, where the first and second nucleotide sequences are located in one or more plasmids.SELECTED DRAWING: None

The invention relates to the technical field of biological medicine, in particular to a nuclear receptor truncated variant and application thereof. According to the truncated variant of the nuclear receptor LBD structural domain provided by the invention, at least one amino acid is deleted at the C terminal. The AR truncated variant can induce transcriptional activation of a downstream signal channel under the condition of deletion of AR-NTD, and a brand new mechanism analysis idea and a treatment target are provided for solving the problem that AR-negative prostate cancer patients are difficult to treat.

The present invention relates to the field of tumor immunology, and particularly relates to a gene editing-based animal model, for efficiently and rapidly screening for tumor antigen-specific B cells, obtaining antibody information, and providing a new target for clinical personalized treatment.

To provide a composition comprising an epitope of a peptide that may elicit an immune response in a subject following administration.SOLUTION: Such a composition may comprise a nucleic acid. The composition may comprise a peptide. The method disclosed herein comprises a step of administering a composition comprising an epitope of a peptide to a subject in need thereof. In some of aspects, the composition disclosed herein comprises [a first plasmid comprising] a first nucleotide sequence encoding a first epitope of a first antigen expressed by a cell associated with breast cancer, and a second plasmid comprising a second nucleotide sequence encoding a second epitope of a second antigen expressed by a cell associated with breast cancer, where the first and second nucleotide sequences are located in one or more plasmids.SELECTED DRAWING: None

The invention belongs to the technical field of gene engineering, and particularly relates to application of nuclear receptor LXRs in regulating and controlling the anti-cancer activity of NK cells. The invention provides an application of nuclear receptor LXRs in preparation of a biomarker for detecting the antitumor activity of NK cells. The LXRs comprise LXRbeta and / or LXRalpha; and the LXR beta is expressed in an SLC9B2 signal channel. The invention discloses the effect of the nuclear receptor LXRs in regulating and controlling the anti-cancer activity of the NK cells for the first time.

The present disclosure provides a method for promoting the sustained effector function of immune cells, comprising modifying the cells to overexpress c-Jun and to reduce the level of NR4A gene and / or protein. Also provided are modified cells, such as immune cells, modified to overexpress c-Jun and to reduce the expression level of NR4A gene and / or protein. Overexpressing c-Jun and simultaneously reducing the expression level of NR4A gene and / or protein results in exhaustion / dysfunction-resistant cells that are both apoptosis-resistant and immune checkpoint-resistant, and also maintain anti-tumor function in the tumor microenvironment.

This invention provides a method for detecting 25-OH-VD using a VDR and RXRα double-sandwich method, comprising: sequentially synthesizing VDR and RXRα sequences, expressing VDR and RXRα, purifying VDR and RXRα; and using the purified VDR and RXRα proteins to detect the content of 25-OH-VD using the double-sandwich method. This invention provides a method for detecting 25-OH-VD content using a VDR and RXRα double-sandwich method, which solves the problems of low accuracy and narrow linear range in competitive methods for detecting 25-OH-VD content. Furthermore, this method is simple to operate, does not require animal immunization for antibody preparation, and saves preparation time and resources.

There remains a need in the art for the production and culture of mature adipocytes that are suitable for human consumption and can be produced in a scalable, cost-effective manner. The present invention relates to pluripotent stem cells comprising an expression construct for the expression of PPAR-γ protein and an expression construct for the expression of CEBPα protein. The present invention further provides a method for producing adipocytes comprising the pluripotent stem cells, and a food product comprising the adipocytes or the pluripotent stem cells.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD) is the most common liver disease with a worldwide prevalence estimated at 30% of the general population. To better understand the influence of MASLD progression on cardiovascular disease, the aim of the study was to develop a new physiopathological mouse model able to develop progressive MASLD, along with atherosclerosis development, in a reasonable period of time. LDLr - / - mice were crossed with PPARα-deficient mice in order to obtain LDLr- / - mice expressing (LDLr - / - PPARα + / +) or not (LDLr - / - PPARα - / -) PPARα. Female mice were challenged with a high-fat diet during 12 and 18 weeks. Histological liver analysis showed that, compared to control diet, LDLr - / - PPARα + / + mice under high fat diet developed mostly steatosis at 12 weeks, and then exhibited all characteristics of human MASLD, namely the steatosis, inflammation and ballooning-triad, with presence of fibrosis at 18 weeks. This MASLD progression over time in LDLr - / - PPARα + / + was aggravated in LDLr - / - PPARα + / + mice. The present invenion defines a new relevant mouse model of progressive MASLD, developing all the characteristics of human MASLD (steatosis, inflammation, ballooning, fibrosis), in a relatively short time period (12-18 weeks), along with simultaneous atherosclerosis development.

The present invention relates to pluripotent stem cell comprising an expression construct for expression of a PPAR-γ protein and an expression construct for expression of a CEBPαprotein. The invention further provides for methods of producing adipocytes comprising the pluripotent stem cells and for foodstuff comprising the adipocytes or pluripotent stem cells.

Provided herein are binding molecules to tumor associated macrophages and associated methods for the treatment and detection of cancer.

Disclosed is an agent for the treatment of a common form of autosomal dominant retinitis pigmentosa (ADRP) wherein the agent comprises a first nucleotide sequence encoding a CRISPR-related (Cas) endonuclease bound to an NG or NNGRRT PAM (Primal Spacer Adjacent Motif) sequence, and a second nucleotide sequence encoding or comprising a guide RNA (gRNA) capable of forming a CRISPR-Cas complex with the Cas endonuclease, wherein the gRNA specifically targets a target mutant allele selected from the group consisting of RHOP23H and NR2E3G56R.

The present invention relates to a pluripotent stem cell comprising an expression construct for expressing a PPAR-gamma protein and an expression construct for expressing a CEBP alpha # protein. The invention further provides methods comprising the production of adipocytes using pluripotent stem cells and foods comprising adipocytes or pluripotent stem cells.

The present disclosure provides polynucleotides that are capable of reducing the level of a NR4A3 gene and / or NR4A3 protein in a cell (e.g., immune cell). In some aspects, the polynucleotides comprises a gRNA that specifically targets a region within the NR4A3 gene. The present disclosure also provides the use of such polynucleotides to treat various diseases or disorders.

A gene delivery system and applications thereof in the technical field of biological medicines that is particularly useful in the preparation of drugs for treatment of tumors are disclosed. The gene delivery system and applications relate to technology for inducing the differentiation of malignant tumor cells into mature cells, in which regulating the expression of HNF4 alpha protein in the malignant tumor cells using messenger ribonucleic acid, the malignant phenotype of the malignant solid tumor cells is inhibited, and the effective treatment of the malignant solid tumors is achieved. The gene delivery system and applications are therefore applicable to a method of preparing a drug for treating malignant solid tumors and to a method of treating a patient having a malignant solid tumor.

The application discloses an application of a nuclear receptor target gene in preparation of a biological preparation for blocking activation of diapause larvae, and relates to the field of biotechnology and parasite prevention and control. According to two nuclear receptor targets of Haemonchus contortus HCON_00101910 (regulating activity of worms) and HCON_00023750 (regulating development of larvae), the two nuclear receptor targets are combined with host progesterone and estradiol and are activated, constitute a key signal path in the spring activation process of diapause larvae, and have no homologous genes in mammals, and the safety is excellent. By constructing specific shRNA lentivirus vectors (the silencing efficiency is all greater than or equal to 60%) targeting the two genes, single target or double target synergistic intervention is realized, and the activity-development double key links of worms in the host body can be specifically blocked. The application provides a new paradigm of preventive prevention and control with high specificity and green safety, and provides core technical support for solving the seasonal epidemic problem of blood fluke disease.

The present invention provides a novel protein and biologically-active fragments and variants thereof with advantageous therapeutic and cosmetic uses. Also provided are methods of using the proteins, as well as methods of producing the proteins using a recombinant cell. Further provided are recombinant host cells transformed with a polynucleotide sequence that encodes the expression of the proteins.

Provided herein are methods, compositions and kits to enhance anti-cancer T-cell therapy. In particular, provided herein are reagents and methodologies to promote anti-cancer T-cell therapy comprising inhibition of retinoic acid receptor alpha (RARα) in chimeric antigen receptor (CAR) T cells.

This document provides methods and materials for treating a mammal (e.g., a human) having or at risk of developing a proteinopathy. For example, one or more importin polypeptides (and / or nucleic acids designed to express an importin polypeptide) can be administered to a mammal (e.g., a human) having or at risk of developing a proteinopathy to treat the mammal.

A novel technique for improving secretory production of a heterologous protein by coryneform bacteria is provided, and thereby a method for secretory production of a heterologous protein is provided. A coryneform bacterium having an ability of secretory producing a heterologous protein and having been modified so that an activity of a Mdh protein is reduced is cultured to produce the heterologous protein by secretory production.

A method of differentiating nonhuman primate iPSCs to neurons may include providing a modified vector comprising a piggyBac vector backbone expressing a differentiation factor gene; treating the nonhuman primate iPSCs with the modified vector in medium; replacing the medium with a second medium including BDNF, NT-3, and laminin; adding medium supplemented with L-glutamine or an L-glutamine alternative, BDNF, and NT3; and producing neuronal lineage cells.

An agent for treating a common form of autosomal dominant retinitis pigmentosa (ADRP) is disclosed, wherein the agent comprises a first nucleotide sequence encoding a CRISPR-associated (Cas) endonuclease which binds to an NG or NNGRRT PAM (protospacer adjacent motif) sequence, and a second nucleotide sequence encoding or comprising a guide RNA (gRNA) capable of forming a CRISPR-Cas complex with said Cas endonuclease, wherein the gRNA is specifically targeted to a target mutant allele selected from RHOP23H and NR2E3G56R.